Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease

David Fitchett; Silvio E. Inzucchi; John M. Lachin; Christoph Wanner; Philippe van de Borne; Michaela Mattheus; Odd Erik Johansen; Hans J. Woerle; Uli C. Broedl; Jyothis T. George; Bernard Zinman; EMPA-REG OUTCOME Investigators

首页> 外文期刊>Journal of the American College of Cardiology >Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease

【24h】

Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease

机译：用2型糖尿病和心血管疾病患者的Empagliflozin减少心血管死亡率降低

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of the American College of Cardiology》 |2018年第3期|共4页
作者
David Fitchett; Silvio E. Inzucchi; John M. Lachin; Christoph Wanner; Philippe van de Borne; Michaela Mattheus; Odd Erik Johansen; Hans J. Woerle; Uli C. Broedl; Jyothis T. George; Bernard Zinman; EMPA-REG OUTCOME Investigators;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心脏、血管（循环系）疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease [J] . David Fitchett, Silvio E. Inzucchi, John M. Lachin, Journal of the American College of Cardiology . 2018,第3期

机译：用2型糖尿病和心血管疾病患者的Empagliflozin减少心血管死亡率降低
2. Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease [J] . Mafalda Ramos, Volker Foos, Anastasia Ustyugova, Diabetes therapy . 2019,第6期

机译：依帕列净与西格列汀和沙格列汀比较的成本-效果分析基于2型糖尿病和已确立的心血管疾病患者的心血管结果试验
3. Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease　― Results From EMPA-REG OUTCOME? ― [J] . Kohei Kaku, Jisoo Lee, Michaela Mattheus, Circulation journal . 2017,第2期

机译：Empagliflozin和亚洲患者的心血管结果2型糖尿病和成立的心血管疾病 - 结果来自Empa-Reg结果？ -
4. An explainable XGBoost–based approach towards assessing the risk of cardiovascular disease in patients with Type 2 Diabetes Mellitus [C] . Maria Athanasiou, Konstantina Sfrintzeri, Konstantia Zarkogianni, IEEE International Conference on Bioinformatics and Bioengineering . 2020

机译：一种可解释的XGBoost基方法，旨在评估2型糖尿病患者心血管疾病风险的方法
5. Life Course Evaluation of a Plant-Centered Diet and Risk of Type 2 Diabetes, Weight Gain, Cardiovascular Diseases, All-Cause Mortality, and Markers of Chronic Kidney Disease: The Coronary Artery Risk Development in Young Adults (Cardia) Cohort [D] . Choi, Yuni. 2021

机译：生命课程评估植物中心的饮食和2型糖尿病风险，体重增加，心血管疾病，慢性肾病的全因死亡率和标志性：年轻成年人的冠状动脉风险发展（Cardia）队列
6. Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo‐controlled double‐blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi‐center placebo‐controlled double‐blind randomized trial [O] . Atsushi Tanaka, Michio Shimabukuro, Noritaka Machii, 2020

机译：次要分析评估Empagliflozin对2型糖尿病患者内皮功能的深刻作用：Empagliflozin对心血管高风险糖尿病内皮功能的安慰剂对照双盲随机作用Mellitus：多中心安慰剂控制双盲随机试验
7. Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo‐controlled double‐blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi‐center placebo‐controlled double‐blind randomized trial [O] . Atsushi Tanaka, Michio Shimabukuro, Noritaka Machii, 2020

机译：次要分析评估Empagliflozin对2型糖尿病患者内皮功能的深刻作用：Empagliflozin对心血管高风险糖尿病内皮功能的安慰剂对照双盲随机作用Mellitus：多中心安慰剂控制双盲随机试验

Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease

著录项

相似文献

相关主题

期刊订阅